Medicine:Beractant
Beractant, also known by the trade name of Survanta, is a modified bovine pulmonary surfactant containing bovine lung extract (phospholipids, neutral lipids, fatty acids, and bovine surfactant proteins), to which synthetic DPPC, tripalmitin and palmitic acid are added. The composition provides 25 mg/mL phospholipids, 0.5 to 1.75 mg/mL triglycerides, 1.4 to 3.5 mg/mL free fatty acids, and <1.0 mg/mL total surfactant proteins.[1] As an intratracheal suspension, it can be used for the prevention and treatment of neonatal respiratory distress syndrome.[2] Survanta is manufactured by Abbvie.
Beractant is on the World Health Organization's List of Essential Medicines.[3]
Generic form
Beraksurf is generic form of Survanta (Beractant) which is manufacturing by Tekzima.
References
- ↑ "A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants". Pediatrics 115 (4): 1018–29. April 2005. doi:10.1542/peds.2004-2183. PMID 15805380.
- ↑ "Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. Survanta in Term Infants Study Group". The Journal of Pediatrics 132 (1): 40–7. January 1998. doi:10.1016/S0022-3476(98)70482-2. PMID 9469998.
- ↑ The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list. Geneva: World Health Organization. 2025.
 |  |
